BICX — Biocorrx Share News
0.000.00%
Last trade - 00:00- $6.28m
- $13.21m
- $0.80m
Brief: Biocorrx Announces Completion Of Treatment Phase Of Study Subjects And Preliminary Safety Data From Phase I Clinical Trial Of Bicx104
Brief: BioCorRx Partners With Government Plus To Expand Its Beat Addiction Recovery Program In The United States
Brief: Biocorrx Completes Final Subject Enrollment In Phase I Clinical Trial Of Bicx104, An Implantable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
Brief: BioCorRx Begins Recruitment for Clinical Trial of BICX104
Brief: Recro And Biocorrx Expand Development And Manufacturing Relationship To Support Bicx104, An Implantable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
Brief: BioCorRx Gets Awarded About $3.5 Mln For Opioid Use Disorder Treatment
Brief: BioCorRx Appoints Finance Veteran Joseph J. Galligan To Board Of Directors
Brief: BioCorRx Inc Says GLP Preclinical Studies Uninterrupted By COVID-19 To Date
Brief: BioCorRx Preclinical Data Suggests VDM-001 May Prevent Fentanyl Overdose
Brief: BioCorRx Provides Update On BICX102